바이오스펙테이터

바이오스펙테이터 김성민 기자

Collaboration to leverage Lunit SCOPE IO ® and SCOPE universal IHC® (uIHC) digital pathology products in two Daiichi Sankyo oncology research and development programs

Lunit announced on the 16th a collaboration with Daiichi Sankyo aimed at accelerating biomarker discovery and optimizing translational research by integrating multiple AI-powered Lunit SCOPE digital pathology products across two oncology pipeline programs.

Daiichi Sankyo will apply various Lunit SCOPE solutions, including SCOPE uIHC for quantitative IHC analysis and SCOPE IO for immune phenotyping and spatial analysis, to explore novel biomarkers and to potentially enrich clinical trials or to potentially support precision patient stratification for select oncology pipeline programs.

The work will include exploratory research projects and analyses across two oncology assets across multiple types of cancer, with the potential to inform future trial designs, biomarker strategies and clinical development plans.

“Lunit SCOPE was built to unlock hidden insights from pathology slides by quantifying the tumor microenvironment, predicting molecular profiles, and generating data-rich features to inform trial design,” said Brandon Suh, CEO of Lunit.

“SCOPE uIHC is now enabling the next generation of IHC-based biomarkers,” Suh added. “By working with Daiichi Sankyo, we are embedding these capabilities into translational and clinical research, enabling faster biomarker discovery and more precise patient stratification. Ultimately, this will lead to more efficient trials and better outcomes, giving each patient a greater chance of receiving the therapy that works best for them.”